Uncategorized

Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes

Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes

Published

on

With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version